Search

Displaying results 4921 - 4930 of 10000 in total
  1. Drug

    Octylphenoxy polyethoxyethanol

    go.drugbank.com/drugs/DB04682
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Tetramethrin

    go.drugbank.com/drugs/DB13752
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Fenvalerate

    go.drugbank.com/drugs/DB18391
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    BCc1

    go.drugbank.com/drugs/DB16504
    Experimental

    BCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.

  5. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. … It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes.

  6. Drug

    Safrazine

    go.drugbank.com/drugs/DB09253
    ApprovedWithdrawn

    Safrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.

  7. Drug

    SOR-C13

    go.drugbank.com/drugs/DB15366
    Investigational

    SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).

    Categories: Ion Channels
  8. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  9. Drug

    Gosogliptin

    go.drugbank.com/drugs/DB08382
    Investigational

    Gosogliptin has been used in trials studying the treatment of Renal Insufficiency, Chronic.

    Categories: DPP-IV Inhibitors
  10. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    It is being developed by Peptech. … PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.